Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Vitamina D en lupus eritematoso sistémico con y sin nefritis lúpica / Vitamin D in systemic lupus erythematosus with and without lupus nephritis
Resumen
Resumen
Introducción: Las concentraciones séricas subóptimas de vitamina D se presentan en múltiples enfermedades crónicas, como las enfermedades autoinmunitarias. Los objetivos del estudio fueron: 1) comparar las concentraciones séricas de 25-hidroxivitamina D (25OHD3) en pacientes con lupus eritematoso sistémico (LES) con y sin nefritis lúpica (NL), y 2) evaluar la asociación de las concentraciones séricas de 25OHD3 con la actividad de la enfermedad.
Material y métodos: Estudio comparativo, transversal, que incluyó 48 mujeres con LES, con y sin NL. Se excluyeron aquellas con enfermedad renal crónica en estadio IV, cáncer, hiperparatiroidismo, embarazo o lactancia. La actividad fue evaluada con el instrumento SLEDAI-2K. La concentración sérica de 25OHD3 se determinó mediante inmunoanálisis quimioluminiscente.
Resultados: La media de edad de las pacientes con y sin NL fue de 36.3 ± 8.6 años y 42.7 ± 7.6 años, respectivamente. Se observó una elevada prevalencia de valores subóptimos de 25OHD3 en todas las pacientes (93%). Las concentraciones séricas de 25OHD3 fueron diferentes entre pacientes con y sin NL: 21.5 ± 6.8 ng/ml frente a 19.2 ± 7.1 ng/ml (p = 0.362). No se encontró correlación entre la concentración sérica de 25OHD3 y la actividad de la enfermedad (r = −045, p = 0.761).
Conclusiones: En pacientes con LES, las concentraciones séricas de 25OHD3 fueran diferentes entre pacientes con y sin NL; sin embargo, esta diferencia no fue significativa. Además, no se encontró correlación entre las concentraciones séricas de 25OHD3 y la actividad de la enfermedad evaluada por SLEDAI-2K.
Abstract
Background: Sub-optimal serum vitamin D levels occur in multiple chronic diseases such as autoimmune diseases. The objectives of this study were: 1) compare the serum concentration of 25-hidroxivitamin D (25OHD3) in patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN), and 2) evaluate the association of serum concentration of 25OHD3 with the activity of the disease.
Material and methods: A comparative, cross-sectional study was conducted, including 48 women with SLE, with and without clinical diagnosis of LN, according to the score of renal activity evaluated by SLEDAI-2K. Patients with stage IV chronic kidney disease, cancer, hyperparathyroidism, pregnancy and lactation were excluded. The activity was evaluated by the SLEDAI-2K instrument. The serum concentration of 25OHD3 was assessed by chemiluminescent immunoassay.
Results: The mean age of patients with and without LN was 36.3 ± 8.6 and 42.7 ± 7.6 years, respectively. High prevalence of suboptimal 25OHD3 levels was observed (93%). 25OHD3 concentrations were different between patients with and without LN, 21.5 ± 6.8 ng/mL vs. 19.2 ± 7.1 ng/mL (p = 0.362). No correlation was found between serum 25OHD3 concentration (r = −045, p = 0.761).
Conclusions: There were no differences found in serum concentrations of 25OHD3 in patients with or without NL. Moreover, no correlation was found between serum 25OHD3 levels and the activity of the disease evaluated by SLEDAI-2K
Palabras clave
Referencias
Schneider L, Dos Santos ASP, Santos M, da Silva-Chakr RM, Monticielo OA. Vitamin D and systemic lupus erythematosus:state of the art. Clin Rheumatol. 2014;33(8):1033-8.
Amital H, Szekanecz Z, Szücs G, DankóK, Nagy E, Csépány T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity:is it time to routinely supplement patients with SLE with vitamin D?Ann Rheum Dis. 2010;69(6):1155-7.
Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin D levels in Chinese patients with systemic lupus erythematosus:relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford). 2012;51(4):644-52.
García-Mira Y, Heredia S, Martínez-Morillo L, Gifre L, Prior-Español A, Camins J, et al. AB0544 Levels of vitamin D in a cohort of patients with systemic lupus erithematosus. Relationship with disease activity and bone mass. Ann Rheum Dis. 2017;76:1241.
Sahebari M, Nabavi N, Salehi M. Correlation between serum 25(OH)D values and lupus disease activity:an original article and a systematic review with meta-analysis focusing on serum VitD confounders. Lupus. 2014;23(11):1164-77.
Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus:a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.
Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus:modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013;65(7):1865-71.
Sumethkul K, Boonyaratavej S, Kitumnuaypong T, Angthararuk S, Cheewasat P, Manadee N, et al. The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. Rheumatol Int. 2013;33(6):1461-7.
Kumar R, Tebben PJ, Thompson JR. Vitamin D and the kidney. Arch Biochem Biophys. 2012;523(1):77-86.
De Bragança AC, Volpini RA, Mehrotra P, Andrade L, Basile DP. Vitamin D deficiency contributes to vascular damage in sustained ischemic acute kidney injury. Physiol Rep. 2016;4(13):e12829.
Lai S, Coppola B, Dimko M, Galani A, Innico G, Frassetti N, et al. Vitamin D deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease. Ren Fail. 2014;36(1):58-64.
Volchenkov R, Karlsen M, Jonsson R, Appel S. Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells. Scand J Immunol. 2013;77(4):246-54.
Yazdanpanah E, Mahmoudi M, Sahebari M, Rezaieyazdi Z, Esmaeili S-A, Tabasi N, et al. Vitamin D3 alters the expression of toll-like receptors in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. J Cell Biochem. 2017;118(12):4831-5.
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21.
Pons-Estel GJ, Alarcon GS, Burgos PI, Hachuel L, Boggio G, Wojdyla D, et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance:data from a Latin American cohort. Lupus. 2013;22(9):899-907.
Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis:racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-54.
Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus. 2017;26(11):1139-48.
Mok CC, Kwok RCL, Yip PSF. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-60.
Birmingham DJ, Bitter JE, Ndukwe EG, Dials S, Gullo TR, Conroy S, et al. Relationship of circulating anti-C3b and anti-C1q IgG to lupus nephritis and its flare. Clin J Am Soc Nephrol. 2016;11(1):47-53.
Gupta R, Aggarwal A, Sinha S, Rajasekhar L, Yadav A, Gaur P, et al. Urinary osteoprotegerin:a potential biomarker of lupus nephritis disease activity. Lupus. 2016;25(11):1230-6.
Lee YH, Bae S-C. Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis:an update meta-analysis. Rheumatol Int. 2015;35(5):815-23.
Xing C, Chen M, Mao H. Study of 25-OH vitamin D3 in patients with lupus nephritis and its relationship with the disease activity. Nephrology. 2016;21:113.
Yu Q, Qiao Y, Liu D, Liu F, Gao C, Duan J, et al. Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy. Arthritis Res Ther. 2019;21(1):19.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
Kendrick J, Andrews E, You Z, Moreau K, Nowak KL, Farmer-Bailey H, et al. Cholecalciferol, calcitriol, and vascular function in CKD:a randomized, double-blind trial. Clin J Am Soc Nephrol. 2017;12(9):1438-46.
Aly MG, Zhu L, Weimer R, Opelz G, Morath C, Kuon R, et al. Low utility of serum 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 in predicting peripheral Treg and Th17 cell counts in ESRD and renal transplant patients. Transpl Immunol. 2017;43-44:3-10.
Conkar S, Mir S. Relationship of insulin resistance to vitamin d status in children with nondiabetic chronic kidney disease. Saudi J Kidney Dis Transpl. 2017;28(5):1078-84.
Kumar V, Yadav AK, Lal A, Kumar V, Singhal M, Billot L, et al. A randomized trial of vitamin D supplementation on vascular function in CKD. J Am Soc Nephrol. 2017;28(10):3100-8.
Mansouri L, Lundwall K, Moshfegh A, Jacobson SH, Lundahl J, Spaak J. Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease —a randomized trial. BMC Nephrol. 2017;18(1):161.
DOI: https://doi.org/10.24875/RMIMSS.M20000063
Enlaces refback
- No hay ningún enlace refback.